Autolus Therapeutics (AUTL) 46th Annual William Blair Growth Stock Conference summary

Commercial progress and financial performance

• Lead CAR T-cell therapy approved for relapsed/refractory acute leukemia, launched in the U.S. and U.K., with 2023 revenues of GBP 74 million and market leadership in its indication.

• Achieved positive gross profit margin in Q1 2024, with revenue guidance for 2024 at $120–$135 million and expansion to over 80 U.S. centers expected.

• Manufacturing facility north of London supports individualized therapy with >90% success rate, doubling output in 2024 while reducing costs.

• Gross profit margin projected to mature at 65–70%, with ongoing operational optimization to drive profitability.

• U.K. launch deemed cost-efficient, with direct routine commissioning and no need for additional data to justify pricing.

Clinical data and product differentiation

• Real-world data from the ROCCA Consortium showed >90% complete remission rate, no high-grade cytokine release syndrome, and no treatment-related mortality.

• Product’s safety profile enables treatment of older and sicker patients previously ineligible for CAR T therapy, expanding the addressable market.

• Pediatric pivotal study ongoing, with data expected by end of 2025; phase I data showed >90% remission and good safety.

• Unique ability to reset the B-cell compartment, eradicate B cells in CNS, and address autoimmune diseases like lupus nephritis and progressive multiple sclerosis.

• Early lupus nephritis data show rapid, deep symptom improvement and steroid reduction in most patients.

Pipeline and future milestones

• Pivotal pediatric leukemia study and lupus nephritis pivotal study underway, with key data readouts expected end of 2025 and mid-2028, respectively.

• Progressive MS (BOBCAT study) to provide initial data by end of 2024 and full data in 2025.

• AUTO8 in light chain amyloidosis to report data by end of 2024.

• Upcoming presentations at EULAR and European Hematology Association meetings, with further updates on lupus and MS studies planned.

• Expansion into larger autoimmune indications offers significant growth potential beyond rare leukemia markets.